DIL has received an approval to sign a Term Sheet to acquire 3,830,072 equity shares in its subsidiary, Fermenta Biotech (FBL), representing 21.05% of the issued and paid-up capital of FBL, from Evolvence India Life Sciences Fund LLC, a Private Equity Investor. The Board of Directors of the company at its meeting held on October 11, 2017 have authorised the same.
DIL (earlier known as Duphar-Interfran) is a well-respected public listed company. It has built a stellar reputation for itself in the arenas of pharmaceuticals, biotechnology, environmental solutions and other segments including Entertainment and Health & Wellness.
